NextPlat (NXPL) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $14.5M, down from $17.5M year-over-year, mainly due to declines in Healthcare segment sales, 340B contract revenue, and lower prescription volumes.

• E-commerce segment saw growth in recurring airtime revenue, up 51% year-over-year, and benefits from the Outfitter acquisition, but hardware sales declined and tariffs delayed the Florida Sunshine launch in China.

• Net loss attributable to shareholders narrowed to $1.3M, or ($0.05) per share, as operating expenses fell 26% due to cost controls and elimination of non-recurring items.

• Strategic alternatives, including possible sale, merger, or partnerships, are being evaluated to maximize shareholder value.

• Management remains focused on cost reduction, efficiency, and strategic planning amid rising drug prices, litigation, and potential tariff impacts.

Financial highlights

• Q1 2025 revenue: $14.5M (Q1 2024: $17.5M); e-Commerce up 5% to $3.0M, Healthcare down 11% to $10.1M.

• Gross profit margin declined to 23.8% from 27.8% year-over-year, impacted by lower 340B contract revenue and increased e-Commerce airtime costs.

• Operating expenses fell 26% to $4.9M, reflecting elimination of non-recurring costs such as impairment loss, fully vested stock-based compensation, and merger-related fees.

• Net loss: $1.3M (Q1 2024: $1.5M); EPS $(0.05) vs. $(0.08) prior year.

• Ended the quarter with $17.7M in cash and $22.1M in working capital.

Outlook and guidance

• Tariff escalation between the US and China has paused the Florida Sunshine product launch in China; alternative markets and production strategies are being explored.

• New 340B pharmacy service agreements are expected to drive revenue growth and improve margins in Healthcare Operations.

• Regulatory approval for OPKO pet health products in China anticipated by Q4, with sales to begin ~12 weeks after approval.

• Ongoing cost reduction and operational efficiency initiatives are expected to continue, with existing cash resources supporting operations for at least 12 months.

• Strategic alternatives, including business sales, mergers, and new ventures, are being explored.